A Feasibility study of MRI and PET Imaging to Assess Response toMK-3475 (Pembrolizumab) in Patients with Metastatic Melanoma
Study for patients with metastatic melanoma receiving therapy with Keytruda using imaging techniques to observe change in tumor size
Sponsor: Merck & Co., Inc
Enrolling: Male and Female Patients
IRB Number: AAAO2558
Contact: Lauren Taiclet: 212-305-0455 / lt2646@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test two imaging techniques, one called whole body diffusion weighted magnetic resonance imaging (WB-DWI MRI), and another called F-18 3-deoxy-3-fluorothymidine PET (F-18-FLT PET). The goal is to see whether these imaging techniques would allow the study doctors to see changes in the size of a tumor earlier for patients with metastatic melanoma receiving MK-3475.
This study is closed
Investigator
Yvonne Saenger, MD
Do You Qualify?
Do you have an untreated brain metastases or active central nervous system metastases? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Lauren Taiclet
lt2646@cumc.columbia.edu
212-305-0455
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE